aflibercept vs netarsudil
Side-by-side comparison of aflibercept and netarsudil Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Eylea
Rhopressa
AHZANTIVE is a medicine used to treat certain eye problems. It helps to stop blood vessels from growing and leaking in the eye.
Rhopressa is an eye drop medicine. It helps lower pressure in the eye.
AHZANTIVE treats wet age-related macular degeneration (AMD). It also treats swelling in the macula (the central part of the retina) caused by retinal vein occlusion (RVO) or diabetic macular edema (DME). Additionally, it can treat diabetic retinopathy (DR), an eye disease caused by diabetes.
Rhopressa is used to lower high pressure inside the eye. This high pressure can be caused by open-angle glaucoma or ocular hypertension. By lowering the pressure, Rhopressa helps to prevent damage to the optic nerve and vision loss.
AHZANTIVE is a VEGF inhibitor. VEGF is a protein that promotes the growth of new blood vessels. By blocking VEGF, AHZANTIVE helps to reduce the growth of abnormal blood vessels in the eye and decrease leakage.
Rhopressa belongs to a class of drugs called Rho kinase inhibitors. It works by helping fluid drain better from the eye. This lowers the pressure inside the eye.
- • Bleeding in the eye
- • Eye pain
- • Clouding of the lens of the eye (cataract)
- • Separation of the vitreous gel from the retina
- • Spots in your vision
- • Eye redness (53%)
- • Corneal verticillata (20%)
- • Pain where the drop is applied (20%)
- • Bleeding in the eye (20%)
- Death 7,853
- Trouble seeing 2,013
- Using the medicine for something it's not approved for 1,509
- Loss of sight 1,459
- Eye infection 1,372
- Eye redness 244
- Blurred vision 149
- Using the medicine for something it's not approved for 145
- Eye pain 134
- Eye redness 133
Injections with AHZANTIVE may cause serious eye infections (endophthalmitis), separation of the retina (retinal detachment), and inflammation of blood vessels in the retina. Tell your doctor right away if you have any signs of these problems. AHZANTIVE may also increase the risk of blood clots that can cause stroke or heart attack.
Some patients have developed swelling of the cornea while using Rhopressa. Tell your doctor if you have eye pain or vision changes. Using multi-dose bottles of eye drops can sometimes cause bacterial infections of the cornea.
It is not known if AHZANTIVE can harm an unborn baby. AHZANTIVE should be used during pregnancy only if the benefit justifies the risk. It is also not known if AHZANTIVE passes into breast milk.
It is not known if Rhopressa will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Rhopressa passes into breast milk. Talk to your doctor about breastfeeding while using this medicine.
Also Compare — Nearby Drugs
Compare aflibercept with
How to Read This aflibercept vs netarsudil Comparison
aflibercept is classified in the Anti-VEGF (Ophthalmic Injection) drug class, while netarsudil sits within the Rho Kinase Inhibitor (Ophthalmic) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aflibercept has 14,206 submissions while netarsudil has 805. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aflibercept and netarsudil — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.